Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• The etonogestrel subdermal implant (ESI) demonstrated high clinical effectiveness with an overall Pearl Index ranging from 0 to 1.4, indicating low contraceptive failure rates. One-year continuation rates for ESI varied from 57% to 97%, decreasing to 44-95% by the second year and 25-78% by the third year.
• Comparatively, continuation rates for the levonorgestrel intrauterine system (LNG-IUS) and the copper intrauterine device (Cu-IUD) were higher than for ESI, with odds ratios for 1-year continuation rates of 1.55 (95% CI (confidence interval): 1.36, 1.76) for LNG-IUS and 1.34 (95% CI: 1.13, 1.58) for Cu-IUD.
• In post-abortion settings, simultaneous administration of the progestogen-only contraceptive implant (same as ESI) with mifepristone was associated with reduced rates of subsequent unintended pregnancies and increased patient satisfaction compared to delayed administration.
• The most commonly reported side effect of the etonogestrel subdermal implant (ESI) was abnormal menstruation, with no significant changes in bone mineral density observed at the one-year follow-up.
• In the post-abortion setting, there were no significant adverse outcomes associated with simultaneous administration of the progestogen-only contraceptive implant (ESI) with mifepristone, though early insertion of intrauterine contraceptives (IUC) post-abortion was linked to higher expulsion rates compared to delayed insertion.
• There is no population type or subgroup information available in the reviewed studies.